Cargando…

Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study

OBJECTIVE: Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Jie, Li, Hui, Du, Wei, Yu, Ping, Guan, Ying-Yun, Ma, Shi-Yu, Liu, Dong, Chen, Wei, Shi, Guo-Chao, Bian, Xiao-Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530276/ https://www.ncbi.nlm.nih.gov/pubmed/33071781 http://dx.doi.org/10.3389/fphar.2020.560209

Ejemplares similares

Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021)

A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants
por: Dong, Yidan, et al.
Publicado: (2022)

Efficacy of arbidol in COVID-19 patients: A retrospective study
por: Wei, Shuo, et al.
Publicado: (2021)

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
por: Li, Hailong, et al.
Publicado: (2021)

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
por: Chen, Chang, et al.
Publicado: (2021)

Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial
por: Zheng, Jin-ping, et al.
Publicado: (2023)

The efficacy of combined therapy of qingfeiPaidu capsule and lianhuaqingwen capsule nursing interventions for hospitalized patients with COVID-19: A retrospective study of medical records
por: Li, Yan, et al.
Publicado: (2022)

Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials
por: Fan, Zheng, et al.
Publicado: (2021)

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
por: Li, Yueping, et al.
Publicado: (2020)

Arbidol: The current demand, strategies, and antiviral mechanisms
por: Kang, Yue, et al.
Publicado: (2023)

Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: A systematic review and meta-analysis
por: Liu, Ming, et al.
Publicado: (2021)

Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases
por: Shen, Pan, et al.
Publicado: (2021)

Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule
por: Lan, Xiao-fang, et al.
Publicado: (2021)

A trial of arbidol hydrochloride in adults with COVID-19
por: Zhao, Jingya, et al.
Publicado: (2022)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
por: Li, Ling, et al.
Publicado: (2023)

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
por: Yang, Chunguang, et al.
Publicado: (2020)

Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study
por: Zhou, Xianlong, et al.
Publicado: (2021)

Beneficial effect of Arbidol in the management of COVID-19 infection
por: Jie, Xiong, et al.
Publicado: (2021)

Synthesis and biological activity of water-soluble polymer complexes of arbidol
por: Eropkin, M. Yu., et al.
Publicado: (2010)

A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019
por: Wang, Xuemei, et al.
Publicado: (2020)

The Antiviral Drug Arbidol Inhibits Zika Virus
por: Fink, Susan L., et al.
Publicado: (2018)

Arbidol as a broad-spectrum antiviral: An update
por: Blaising, Julie, et al.
Publicado: (2014)

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial
por: Hu, Ke, et al.
Publicado: (2021)

The clinical efficacy and safety research of Lianhuaqingwen (LHQW) in treatment of COVID-19: A systematic review and meta-analysis
por: Fang, Ling, et al.
Publicado: (2022)

Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial
por: Gong, Xiaowei, et al.
Publicado: (2021)

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo
por: Zhong, Qiong, et al.
Publicado: (2009)

Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis
por: Zaazouee, Mohamed Sayed, et al.
Publicado: (2022)

Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission: A Preliminary Report of a Retrospective Cohort Study
por: Zhang, Jin-nong, et al.
Publicado: (2020)

A new perspective to improve the treatment of Lianhuaqingwen on COVID-19 and prevent the environmental health risk of medication
por: Gu, Wenwen, et al.
Publicado: (2022)

Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
por: Amani, Behnam, et al.
Publicado: (2021)

Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic
por: Liang, Chengyuan, et al.
Publicado: (2021)

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
por: Wang, Xi, et al.
Publicado: (2020)

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
por: Runfeng, Li, et al.
Publicado: (2020)

Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant Klebsiella pneumoniae Infections a Retrospective Study
por: Fang, Jie, et al.
Publicado: (2021)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study
por: Yin, Peng, et al.
Publicado: (2021)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

Effect of Lianhuaqingwen Capsules on Airway Inflammation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Dong, Liang, et al.
Publicado: (2014)

Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections
por: Zhou, Lijuan, et al.
Publicado: (2018)

Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study
por: Xu, Ping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2hkrj1ehisjj8q2bb8pv4e27dg